Cargando…
Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges
The COVID-19 pandemic has presented challenges for traditional models of opioid use disorder treatment worldwide. Depot buprenorphine became available in Australia shortly before the height of the COVID-19 pandemic. This timing provided us an opportunity to examine the utilization and uptake of depo...
Autores principales: | Arunogiri, Shalini, Lintzeris, Nicholas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711199/ https://www.ncbi.nlm.nih.gov/pubmed/33303254 http://dx.doi.org/10.1016/j.jsat.2020.108221 |
Ejemplares similares
-
Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial
por: Lintzeris, Nicholas, et al.
Publicado: (2021) -
Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings
por: Dunlop, Adrian J., et al.
Publicado: (2021) -
Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021) -
Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model
por: Ling, R., et al.
Publicado: (2022) -
Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic
por: Mattocks, Kristin M., et al.
Publicado: (2022)